American Research Products

antibody

Anti-CD55, Decay Accelerating Factor (DAF)-PE

08-9404-4

50 tests

439.00 USD

monoclonal

mouse

PE

western blot, immunohistochemistry, flow cytometry

08-9404-4

Anti-CD55, Decay Accelerating Factor (DAF)-PE

Mouse

monoclonal

PE

Mouse monoclonal

50 tests

439.00 USD

BRIC 216

Mouse IgG1kappa light chain

Mouse monoclonal antibody to human CD55, Decay Accelerating Factor (DAF)-PE conjugate. CD55 is the complement regulatory protein decay accelerating factor (DAF)1. It is a 70kDa (in erythrocytes) glycoprotein anchored in the membrane by a glycosylphosphatidylinositol tail. In other cells the apparent molecular weight is somewhat larger. It has a substantial content of O- glycans, and also one N- glycan. The amino acid sequence (derived from the cDNA) is known. DAF binds to activated C4b or C3b complement fragments on the cell surface, preventing the assembly and accelerating the decay of both classical and alternative pathways. DAF carries the Cromer related blood group antigens2. CD55 was first described on erythrocytes, but is also found on other circulating blood cells3,4. DAF also has a wide distribution on cells in non-haemopoietic tissues, particularly epithelium and endothelium5. CD55 is found specifically at the foetal-maternal interface in placenta6. Soluble forms of DAF are found, for example, in plasma, saliva, urine etc. There are approximately 10,000 CD55 molecules per erythrocyte. CD55 has reduced expression on cells from individuals with paroxysmal nocturnal haemoglobinuria. Individuals with the rare Inab phenotype have an inherited deficiency of CD552. CD55 is also Echo virus7 and Coxackie virus receptor and is a ligand for CD97

BRIC 216 reacts by immunoblotting with a component of 70kDa in non-reduced erythrocyte membranes.The erythrocyte antigen is sialidase and trypsin resistant and pronase, chymotrypsin and AET sensitive. BRIC 216 was used to study the defect which causes absence of DAF from the peripheral blood cells of an individual with the Inab phenotype8. BRIC 216 recognises an epitope on the third short consensus repeat (SCR3) of CD559 and is effective in inhibiting CD55 functional activity. BRIC 216 stains both frozen and fixed tissue sections. BRIC 216 can be used in the monoclonal-antibody-specific immobilisation of erythrocyte antigens (MAIEA) technique when identifying DAF (CD55)11.

Immunoblotting, Immunohistochemistry, Flow Cytometry

2-8°C, do not freeze

1. Lublin D.M. and Atkinson J.P., (1989) Ann. Rev. Immunol. 7, 35-58 (Review).2. Daniels G.L. (1989) Vox Sang. 56, 205-211 (Review).3. Hadam M.R. (1989) in Leucocyte Typing IV; White Cell Differentiation Antigens Ed. W. Knapp et al Oxford University Press pp 694-697.4. Spring FA et al (1987) Immunology 62 307-313.5. Anstee DJ and Spring FA (1989) Transfusion Medicine Reviews 3 13-23.6. Holmes et al., (1990) J. Immunol. 144 3099-3105.7. Bergelson JM et al (1994) Proc. Natl. Acad. Sci. 91 6245-6248.8. Tate CG et al. Biochem. J. 1989, 261: 489-493.9. Coyne KE et al. J. Immunol. 1992, 149: 2906-2913.10. Klickstein LB and Springer TA (1993) Proceedings of the fifth workshop and conference on white cell differentiation antigens, Boston , vol. 2 p1473-1474.11. Petty AC et al (1993) Vox Sang 65 309-315.12. Kolev MV et al. (2010) Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. Pharmacogenomics J 10:12-9

08-9405-1